How do I know if imatinib is working?

For CML, response is measured with BCR-ABL PCR testing — a highly sensitive molecular test that quantifies residual leukemia. Milestones include: complete hematologic response by 3 months, complete cytogenetic response by 12 months, and major molecular response by 18 months. For GIST, CT or PET imaging assesses tumor response. Your oncologist will track these milestones closely.

What happens if I miss doses of imatinib?

Missing doses reduces drug blood levels, allowing leukemic cells to replicate and potentially acquire resistance mutations. Adherence is critically important for maintaining response. If you miss a dose, take it as soon as you remember on the same day. If it is the next day, skip the missed dose and resume your regular schedule.

Can I stop imatinib if I achieve deep remission?

For CML patients who achieve sustained deep molecular response (MR4.5 or better) for at least 2 years, treatment-free remission (TFR) is an option for selected patients under close monitoring. About 40-60% of patients can maintain remission after stopping. This is a decision made carefully with your oncologist, not independently.

Will imatinib affect my fertility?

Imatinib can affect fertility in both men and women. It should not be taken during pregnancy — it is teratogenic and can cause fetal harm. Women of childbearing age must use effective contraception during treatment. Discuss fertility preservation options with your oncologist before starting if relevant.

What to Expect When Starting Imatinib

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting, stopping, or changing any medication. Using this site does not create a doctor-patient relationship.

Drug information changes as the FDA updates labeling, and we cannot guarantee it is complete or current. Verify critical details with your pharmacist or physician.

Emergencies: If you think you may have a medical emergency, call 911 immediately. For a suspected overdose, call Poison Control at 1-800-222-1222. Report side effects to the FDA MedWatch program at fda.gov/medwatch or 1-800-FDA-1088.

See our Terms of Use and Editorial Policy.

Introduction

Imatinib (Gleevec) is a targeted tyrosine kinase inhibitor (TKI) that revolutionized treatment of chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST). It specifically blocks the BCR-ABL protein driving CML and c-KIT/PDGFR driving GIST. Unlike traditional chemotherapy, imatinib is taken orally daily and targets cancer cells specifically, though it still causes significant side effects in many patients.

Week-by-week timeline

Week 1-2

Starting Imatinib

Common early side effects include nausea, diarrhea, fluid retention (swelling around eyes, hands, or feet), muscle cramps, and fatigue. Take imatinib with food and a large glass of water to significantly reduce nausea — this is the single most important tolerability tip. Doses range from 400-800 mg/day depending on indication and response.

Week 2-4

Adjustment and Initial Response

Side effects often stabilize in the first month. Nausea and GI symptoms typically improve with consistent food co-administration. Weight gain from fluid retention may occur. Complete blood count (CBC) is monitored closely — white blood cell and platelet counts may drop initially before recovering.

Month 1-3

Hematologic Response (CML)

For CML: complete hematologic response (normal blood counts) is targeted by 3 months. Your oncologist will monitor BCR-ABL transcript levels by PCR — the measure of treatment success. For GIST: imaging will assess tumor response. Do not stop imatinib without oncologist guidance — stopping can cause rapid disease progression.

Month 3-6

Cytogenetic and Molecular Response

For CML: complete cytogenetic response (no Philadelphia chromosome detectable) is targeted by 12 months. Major molecular response (deep BCR-ABL suppression) is targeted by 18 months. These milestones guide decisions about dose escalation or switching to a newer TKI.

Month 6-12

Long-Term Monitoring

Long-term imatinib use is associated with fluid retention, muscle cramps, skin rash, and rarely cardiac, hepatic, or renal toxicity. Bone density may decrease with long-term use. Consistent daily dosing is critical — missed doses allow leukemic cells to proliferate and acquire resistance mutations.

When to call your doctor

Contact your healthcare provider if you experience:

Rapid weight gain or severe swelling of face, hands, or legs (significant fluid retention or pleural effusion)
Severe chest pain or shortness of breath (possible pleural or pericardial effusion, or cardiac event)
Severe abdominal pain or signs of GI bleeding (GI perforation in GIST patients)
Signs of liver toxicity: yellowing of skin or eyes, dark urine, severe abdominal pain, nausea
Fever with low blood counts (infection risk during myelosuppression)
Unusual bruising or bleeding (low platelet count)
Vision changes or severe headache (rare CNS effects)
Signs of heart failure: worsening shortness of breath, leg swelling, reduced exercise tolerance

Tips for getting started

Take imatinib with food and a large glass of water (at least 8 oz) at the same time each day — this is essential for reducing nausea and is the most effective tolerability measure. Do not crush tablets (bitter taste and reduced absorption). Avoid acetaminophen at high doses (hepatotoxicity risk). Grapefruit juice and St. John's Wort significantly affect imatinib levels — avoid both. Warfarin interacts significantly with imatinib — use LMWH if anticoagulation is needed. Keep all scheduled PCR and CBC monitoring appointments — treatment response data drives critical treatment decisions.

Frequently asked questions

More about Imatinib

Imatinib drug guideSide effects, dosage, interactions, and more Imatinib vs MethotrexateCompare these medications Atorvastatin & ImatinibInteraction details Imatinib & SimvastatinInteraction details

References

[Regulatory] FDA Label: Gleevec (imatinib mesylate) Tablets https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021588s050lbl.pdf Accessed 2026-03-01.
[Regulatory] NIH MedlinePlus: Imatinib https://medlineplus.gov/druginfo/meds/a603016.html Accessed 2026-03-01.
[Regulatory] NCCN CML Guidelines: Tyrosine Kinase Inhibitors https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1488 Accessed 2026-03-01.

Written and fact-checked by PrescriptionDrugs.org Editorial Team

Last updated: March 1, 2026